期刊
GENES AND IMMUNITY
卷 12, 期 1, 页码 40-45出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/gene.2010.46
关键词
IRF5; IFN-beta therapy; herpes virus; multiple sclerosis
资金
- European Community [FP7/2007-2013, 212877]
- Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (Feder) [FIS-PI070353, FIS-PI070369]
- Red Espanola de Esclerosis Multiple [RETICS-REEM RD07/0060]
- Fundacion Alfonso Martin Escudero
- Spanish Health Ministry [CP07/00273]
In recent reports, IRF5 polymorphisms showed significant association with multiple sclerosis (MS) susceptibility in three studied populations and Irf5-deficient mice exhibited an increased susceptibility to viral infection, linked to a significant decrease in the induction of serum type I interferon (IFN). In the present study, we evaluated the association of two IRF5 polymorphisms with MS predisposition and we also addressed whether these polymorphisms were associated with active replication of human herpes virus-6 (HHV-6) observed in a subgroup of MS patients, and/or with response to IFN-beta therapy. A total of 1494 MS patients and 1506 ethnically matched controls were genotyped for rs4728142 and rs3807306 with TaqMan pre-designed assays. One hundred and six patients were classified as responders to IFN-beta therapy (no relapses/increases in EDSS over the 2-year follow-up) and 112 as non-responders (at least two relapses or an increase in expanded disability status scale (EDSS) of at least one point during the same period). The combined analysis of available datasets yielded an effect size on MS with odds ratio (OR)(Mantel-Haenszel) = 1.14 (P<0.002) for the IRF5 polymorphisms rs4728142 and rs3807306. Additionally, trends for association were observed between rs3807306T and infection with HHV-6 [p = 0.05, OR (95% CI)= 1.56 (1.00-2.44)] and response to IFN-beta therapy [P = 0.09, OR (95% CI) 1.39 (0.95-2.05)]. Genes and Immunity (2011) 12, 40-45; doi: 10.1038/gene.2010.46; published online 23 September 2010
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据